viewNetscientific PLC

NetScientific PLC - PDS merger with Edge Therapeutics update

RNS Number : 2254T
NetScientific PLC
19 March 2019

NetScientific plc

("NetScientific" or the "Company")

PDS merger with Edge Therapeutics update


Further to its announcements on 26 November 2018 and 18 March 2019, the Company announces that its ownership of the enlarged PDS Biotechnology Corporation ("PDS"), trading on Nasdaq under the ticker PDSB, on a fully-diluted basis is 8.15%, which at the listing price on 18 March 2019 of $10 values NetScientific's holding in PDS at £4,081,451*. It is the Company's intention to hold the shares and to make a decision on its position in due course.

*Using a US:GBP exchange rate of 1.33


#  #  #

For more information, please contact:


François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO    


Tel: +44 (0)20 3514 1800

WH Ireland Limited (NOMAD, Financial Adviser and Broker)

Chris Fielding / Jessica Cave


Tel: +44 (0)20 7220 1666


Consilium Strategic Communications            

Mary-Jane Elliott / Chris Welsh / Laura Thornton

[email protected]

Tel: +44 (0)20 3709 5700



About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

For more information, please visit the website at http://www.NetScientific.net


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Netscientific PLC

Price: 5.51255

Market: AIM
Market Cap: £4.33 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19